Skip to content Skip to footer
Insights+ Key Biosimilars Events of September 2022

Insights+ Key Biosimilars Events of September 2022

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyBiosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patientsDuring the month of September, Fresenius Kabi’s Stimufend (biosimilar, pegfilgrastim) received the…

Read more